DHSC (UK) · Jul 9, 2026
Guidance: Physical activity guidelines: early years (under 5s)
Infographic explaining the physical activity needed for general health benefits for children under 5 years of age.
Latest medical news · page 84
The latest headlines across every section, pulled from official and open-access sources.
DHSC (UK) · Jul 9, 2026
Guidance: Physical activity guidelines: pregnancy and after childbirth
Infographics explaining the physical activity needed for general health benefits for women in pregnancy and after giving birth.
DHSC (UK) · Jul 9, 2026
Guidance: Physical activity guidelines: adults and older adults
Infographic explaining the physical activity needed for general health benefits for adults and older adults.
DHSC (UK) · Jul 9, 2026
Guidance: Physical activity guidelines: UK Chief Medical Officers' report
A report from the Chief Medical Officers in the UK on the amount and type of physical activity people should be doing to improve their health.
MedCity News · Jul 9, 2026
ACA Marketplace Insurers Propose 14% Median Premium Increase in 2027
KFF found that ACA Marketplace insurers are proposing a median 14% premium increase for 2027, driven by rising healthcare costs and the expiration of enhanced premium tax credits. The post ACA Marketplace Insurers Propose 14% Median Premium Increase in 2027 appeared first on MedCity News .
FDA Drugs · Jul 9, 2026
FDA Actions to Support and Strengthen Domestic Drug Manufacturing
The FDA is taking decisive steps to strengthen U.S. pharmaceutical manufacturing, improve supply chain resilience, and ensure Americans have reliable access to safe, effective, high-quality medicines.
MedTech Dive · Jul 9, 2026
Stereotaxis closes Robocath takeover
With the acquisition of Robocath completed, Stereotaxis intends to accelerate development of next-generation robotic technologies for endovascular procedures.
MedCity News · Jul 9, 2026
Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market
AstraZeneca and Ionis Pharmaceuticals drug eplontersen, brand name Wainua, failed a Phase 3 test in cardiomyopathy caused by transthyretin amyloidosis. More details will be shared at a medical conference next month, but it appears the RNA therapy’s slim hopes now ride on a subgroup analysis. The post Phase 3 Failure Keeps AstraZeneca and Ionis Out of a Growing Heart Disease Market appeared first on MedCity News .
FDA Drugs · Jul 9, 2026
Patient Listening Session Summaries
Patient Listening Session summaries are published after each session to share a high-level summary of the discussion. The Public Engagement Staff draft summaries for FDA-requested sessions and the patient community requester drafts summaries for Patient-led sessions.
FDA Drugs · Jul 9, 2026
eCTD Submission Standards for eCTD v3.2.2 and Regional M1
eCTD Submission Standards
FDA Drugs · Jul 9, 2026
eCTD Submission Standards for eCTD v4.0 and Regional M1
A listing of the Implementation Guides, Specifications, and Documentation that support the FDA implementation for eCTD v4.0
FDA Drugs · Jul 9, 2026
The FDA at 120: A Long, Distinguished History Protecting Americans
Since 1906 Americans have relied on, and benefited from, the FDA’s oversight of our food, medical products, veterinary products, cosmetics, and so much more.
Fierce Biotech · Jul 9, 2026
ARPA-H awards up to $160M to scientists developing custom genetic medicines
The Advanced Research Projects Agency for Health has awarded a new tranche of funds for companies and institutions developing personalized genetic medicines, with the recipient list dominated by high-profile players in the buzzy field.
FDA Drugs · Jul 9, 2026
Preparing Patient and Caregiver Participants for an FDA Patient-Led Listening Session and Suggested Topics
Learn about topics that are outside of the scope of FDA’s work and suggested topics for FDA-Patient-Led Listening Sessions.
Fierce Biotech · Jul 9, 2026
Chutes & Ladders—Idorsia locks in new CEO after shakeup
After Idorsia’s former chief, Srishti Gupta, M.D., left the company upon “mutual agreement” in March, the Swiss drugmaker has now tapped a new leader, Roland Wandeler, Ph.D. Wandeler will officially take over from interim CEO and board chairman Jean-Paul Clozel, M.D., come October 1.
CDC MMWR · Jul 9, 2026
Norovirus, COVID-19, and Influenza Outbreaks Among Residents and Staff Members at the Eaton Wildfire Evacuation Shelter - Pasadena, California, January-February 2025
This report describes illnesses and infection prevention and control protocols at a wildfire evacuation shelter during the Eaton wildfire in Pasadena, California.
CDC MMWR · Jul 9, 2026
Acute Flaccid Myelitis Surveillance - United States, January 2020-December 2025
This report describes acute flaccid myelitis cases reported during 2020-2025.
MedTech Dive · Jul 9, 2026
4 takeaways from MDUFA VI draft agreement
The draft agreement outlines the Food and Drug Administration’s goals for medical device reviews from 2028 to 2032.
FDA Drugs · Jul 9, 2026
Learning and Education to ADvance and Empower Rare Disease Drug Developers (LEADER 3D)
As part of the Accelerating Rare disease Cures (ARC) Program, CDER’s Rare Diseases Team inaugurated the Learning and Education to Advance and Empower Rare Disease Drug Developers (LEADER 3D) initiative. Learn more.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, October 2026 to October 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): October 2026 to October 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, September 2026 to September 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): September 2026 to September 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, August 2026 to August 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): August 2026 to August 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, July 2026 to July 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): July 2026 to July 2027.
UKHSA (UK) · Jul 9, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, June 2026 to June 2027
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): June 2026 to June 2027.